Skip to content

All you need to know about Mounjaro, the antidiabetic injectable also touted as the most powerful weight-loss drug ever

The availability of the drug in India may cause a major disruption in the Indian diabetes care drugs market which is expected to register a CAGR greater than 3.5 percent between 2022 and 2027. The COVID-19 pandemic has contributed a major increase in the market.

Read More

​ The availability of the drug in India may cause a major disruption in the Indian diabetes care drugs market which is expected to register a CAGR greater than 3.5 percent between 2022 and 2027. The COVID-19 pandemic has contributed a major increase in the market. The availability of the drug in India may cause a major disruption in the Indian diabetes care drugs market which is expected to register a CAGR greater than 3.5 percent between 2022 and 2027. The COVID-19 pandemic has contributed a major increase in the market.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish